See more : Central Puerto S.A. (CEPU.BA) Income Statement Analysis – Financial Results
Complete financial analysis of Talaris Therapeutics, Inc. (TALS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Talaris Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BioMarin Pharmaceutical Inc. (BMRN) Income Statement Analysis – Financial Results
- Avadh Sugar & Energy Limited (AVADHSUGAR.BO) Income Statement Analysis – Financial Results
- TPG Pace Beneficial Finance Cor (TPGY-WT) Income Statement Analysis – Financial Results
- SKAGEN – Global (SKIGLO.CO) Income Statement Analysis – Financial Results
- Gibraltar Industries, Inc. (ROCK) Income Statement Analysis – Financial Results
Talaris Therapeutics, Inc. (TALS)
About Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 57.01M | 34.25M | 15.28M | 13.37M |
| General & Administrative | 19.47M | 13.26M | 7.41M | 5.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.47M | 13.26M | 7.41M | 5.01M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 76.48M | 47.51M | 22.68M | 18.38M |
| Cost & Expenses | 76.48M | 47.51M | 22.68M | 18.38M |
| Interest Income | 900.00 | 0.00 | 400.00 | 200.00 |
| Interest Expense | 2.58M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.16M | 623.00K | 447.00K | 379.00K |
| EBITDA | -74.32M | -46.88M | -22.24M | -18.00M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -76.48M | -47.51M | -22.68M | -18.38M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.58M | -326.00K | -23.00K | 223.00K |
| Income Before Tax | -73.89M | -47.83M | -22.71M | -18.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.17M | 326.00K | 23.00K | -223.00K |
| Net Income | -68.73M | -48.16M | -22.73M | -17.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.66 | -16.53 | -34.00 | -28.09 |
| EPS Diluted | -16.66 | -16.53 | -34.00 | -28.09 |
| Weighted Avg Shares Out | 4.12M | 2.91M | 668.51K | 638.33K |
| Weighted Avg Shares Out (Dil) | 4.12M | 2.91M | 668.51K | 638.33K |
Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and...
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index
ATLANTA & NEW YORK--(BUSINESS WIRE)--Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today announced the annual reconstitution of the ICE Biotechnology Index (ICEBIO), which is effective before the open of trading on Monday,...
Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences
BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases,...
Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting
BOSTON and LOUISVILLE, Ky., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American Society of Nephrology (ASN) Kidney Week 2021, taking place November 4-7, 2021.
Das MMORPG „MIR4“ von Wemade erhält im September das erste große Update
SEOUL, Südkorea--(BUSINESS WIRE)--Nach dem erfolgreichen weltweiten Release wird „MIR4“ das erste große Update erhalten. Es werden zusätzliche Inhalte enthüllt, darunter der erste globale Clan-Kampf, die Clan-Challenge und das Einsamkeitstraining. Heute (10. September) wurde ein weiterer Kerninhalt, „Schattental-Eroberung“ (Eroberung des Verborgenen...
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases,...
Talaris Therapeutics Announces Closing of Initial Public Offering
BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune...
U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week
Eight IPOs and four SPACs went public this past week. The week's best performer, Sacramento bank Five Star Bancorp (FSBC) priced at the high end to raise $105 million at a $325 million market cap.
Talaris Therapeutics Announces Pricing of Initial Public Offering
BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain...
Ägypten fasziniert die Welt mit einem Pharaonenumzug in goldenen Wagen
Kairo--(BUSINESS WIRE)--Zweiundzwanzig Pharaonenmumien wurden am Samstagabend in einer bezaubernden königlichen Prozession vom Ägyptischen Museum am Tahrirplatz durch die Straßen von Kairo ins neue Nationalmuseum für Ägyptische Zivilisation (NMEC) in Fustat gefahren. Die Veranstaltung kennzeichnete die offizielle Eröffnung des NMEC. Vor...
Source: https://incomestatements.info
Category: Stock Reports